Safety Reporting IN Clinical Trials

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

GCP for Emergency Medicine
AEs, SAEs, and EAEs – An Overview
ADVERSE EVENT REPORTING
Pharmacovigilance Dr. Muiris Dowling,
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Elements of a clinical trial research protocol
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Pharmacovigilance Lindsey Connery Pharmacovigilance Manager, Cancer Research UK Clinical Trials Unit, Glasgow.
Pharmacovigilance and Risk Management Chapter 17.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
Paula Nicholson Research Facilitator
SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Investigational New Drug Application (IND)
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
Adverse Event Reporting & SAE Reporting for Investigators Trial Number: (POLO-AML-2) Date of training:23 February 2013 Trainer: Deepa Sachdev Venue:Investigator.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
Agenda Introduction Study Objectives Study Design Delegation
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
GCP for Emergency Medicine.  This presentation is intended for emergency physicians involved in recruiting patients to clinical trials and/or caring.
Module 6 Monitoring Events Supposedly Attributable to Vaccination or Immunization (ESAVIs) Training for Inactivated Poliovirus Vaccine (IPV) introduction.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
GCP (GOOD CLINICAL PRACTISE)
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Safety Reporting V6.0 17/01/17.
Assessing expectedness of an adverse event
EudraVigilance.
8. Causality assessment:
Administering Informed Consent Issues for Discussion
Expedited Adverse Event Reporting Requirements
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Remote Monitoring of Adverse Events
Copenhagen University Hospital Rigshospitalet, Denmark
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
Remote Monitoring of Adverse Events
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Adverse Event Reporting _____________________________
Dr Tim England TICH-2 SAE adjudicator
Good clinical practice
Serious Adverse Event Reconciliation
Presentation transcript:

Safety Reporting IN Clinical Trials

Background Many agencies across the world have pharmacovigilance requirements. The Medicines for Human Use (Clinical Trials) Regulations 2004 transposed ICH-GCP requirements into European law and set out the legal requirements for pharmacovigilance in clinical trials involving participants that evaluate medicines from Europe. The Albumen used in this trial is being provided by Baxter, from Europe and so they have a legal requirement to monitor the trial More that that. We, as investigators, have an ethical and scientific obligation to ensure optimum safety reporting

Background The Regulations/ requirements cover: Definitions of adverse events, The responsibilities of investigators for recording of adverse events and the notification of adverse events to sponsors The responsibilities of sponsors for reporting to regulatory authorities and RECs including expedited reports of SUSARs and regular Safety Reports.

Background Most agencies (sponsors, country regulators) accept in principle that a risk-based approach to trial management and monitoring is appropriate. This includes the management of pharmacovigilance. For each clinical trial a risk assessment should generally be undertaken at the protocol development stage. This may be used to plan the details of the approach to pharmacovigilance taken for the trial. We have done this for FEAST as seen in the protocol

Definitions Adverse Event (AE) Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment Comment: An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not considered related to the investigational medicinal product.

Definitions Adverse Reaction (AR) Any untoward and unintended responses to an investigational medicinal product related to any dose administered Comment: All adverse events judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medicinal product qualify as adverse reactions. The expression “reasonable causal relationship” means to convey in general that there is evidence or argument to suggest a causal relationship.

Definitions Unexpected Adverse Reaction (UAR) An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g. investigator’s brochure for an unauthorised investigational product or summary of product characteristics for an authorised product) Comment: When the outcome of the adverse reaction is not consistent with the applicable product information this adverse reaction should be considered as unexpected.

Definition of Seriousness Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) or Suspected Unexpected Serious Adverse Reaction (SUSAR) Any AE, AR or UAR that at any dose: results in death is life-threatening* requires hospitalisation or prolongation of existing hospitalisation results in persistent or significant disability or incapacity consists of a congenital anomaly or birth defect

Definition of Seriousness Medical judgement should be exercised in deciding whether an adverse event/ reaction is serious in other situations. Important adverse events/ reactions that are not immediately life-threatening or do not result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above, should also be considered serious. Life-threatening in the definition of a serious adverse event or serious adverse reaction refers to an event in which the subject was at risk of death at the time of event. It does not refer to an event which hypothetically might have caused death if it were more severe. .

Risk Assessment – type of events being collected Due to the risk associated with the clinical trial and the nature of the study it was concluded that is it appropriate to reasonable to just collect SAE’s The proposed safety recording, notification and reporting procedures is detailed in the trial protocol and safety reporting SOP

Assessment Assessment of an adverse event covers three main areas: Assessment of Seriousness Assessment of Causality Assessment of Expectedness

Assessment of Seriousness results in death is life-threatening requires hospitalisation or prolongation of existing hospitalisation results in persistent or significant disability or incapacity consists of a congenital anomaly or birth defect Note: The term “severe” is often used to describe the intensity (clinical severity) of a specific event. This is not the same as “serious,” which is a regulatory definition based on patient/event outcome or action criteria. For example, a headache may be severe but not serious while a minor stroke may be serious but not severe.

Assessment of Expectedness The evaluation of expectedness is based on knowledge of the adverse reaction and any relevant product information. What might we expect to see? very little it is very safe AE’s reported have been…..

Adverse Events: Sponsor Responsibilities The Regulations require the sponsor to keep detailed records of all adverse events relating to a clinical trial of which they have been notified by investigators in that trial. The sponsor may be required to submit these records to the licensing authoritys on request. Responsibility for reporting to the relevant competent authorities and to the Ethics committee rests with the Sponsor (or the entity to whom this responsibility has been delegated). The agreed responsibilities for each trial should be documented in the protocol and also in the SOPs for the trial.

Expedited Reporting The Regulations set time limits for expedited reporting: Fatal or life threatening SUSARs: Not later than 7 calendar days after the sponsor has information that the case reported fulfils the criteria for a fatal or life-threatening SUSAR, with any follow up information to be reported within a further 8 calendar days. All other SUSARs: Not later than 15 calendar days after the sponsor has information that the case fulfilled the criteria for a SUSAR.

Expedited Reporting As well as SUSARs the following safety issues require expedited reporting: Single case reports of an expected serious adverse reaction with an unexpected outcome (e.g.: a fatal outcome) An increase in the rate of occurrence of an expected serious adverse reaction, which is judged to be clinically important Post-study SUSARs that occur after the patient has completed a clinical trial and are notified by the investigator to the sponsor should be reported to the manufacturer indefinitely. 

Role of the DSMB FEAST has an independant data safety and monitoring committee to oversee the safety of the children in the trial. The DSMB reports to the Trial Steering Committee (TSC). Any serious safety issues identified by the DSMB will be reported to the investigators, to Baxter and the ERCs